Francesca Barone, CSO of Candel Therapeutics, was recently interviewed by Benzinga.

Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials.

Ms. Barone spoke about the company's work in deadly brain cancers. Its candidate, CAN-3110, is currently undergoing phase 1 trials. It recently published exciting data from the trial showing promising results.